We show here that an increased proportion of tamoxifen-resistant CBCs, i. e. tumors developed during adjuvant tamoxifen treatment, were HIF-1α positive and that HIF-1α-positivity in the tumors led to increased breast cancer mortality (BCM). This evidence concerns the gene HIF1A and blue cone monochromacy.